The product is 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid, CAS 7365-45-9, molecular formula C₈H₁₈N₂O₄S, relative molecular mass 238.30 g/mol. The substance is supplied as a pharmaceutical-grade free-acid crystalline powder, with the model designation HEPES Pharma Grade API and packaging variants distinguished by intended route: oral-grade material for tablet, capsule, and granule dosage forms, and low-endotoxin injectable-grade material for parenteral solutions. Its pK_a is 7.55 at 20 °C and 7.31 at 37 °C, giving a useful pH range of 6.8–8.2. The molecule is a zwitterionic N-substituted taurine derivative, not a primary amine; this structural feature separates HEPES from Tris in reactions with reducing sugars, aldehydes, and amine-reactive crosslinking agents. Compared with phosphate buffers, HEPES does not precipitate calcium or magnesium ions at physiological concentrations. These properties support pH control in oral solid-dose processing and in injectable formulation where buffering capacity must be maintained without polyvalent-ion incompatibility.

The pharma-grade designation differs from technical-grade HEPES principally in endotoxin control, residual metal content, and particle size documentation. Technical-grade material used in cell culture research may release with undetermined endotoxin load and broad particle size; pharma-grade API is supplied with a certificate of analysis referencing ICH Q7 expectations for active pharmaceutical ingredients or excipients. This is the critical difference when the same chemical is moved from laboratory buffer preparation into GMP manufacturing of oral and injectable products.

Pharmacopoeial release specifications for injectable-grade HEPES are built from ICH Q7 general chapters

Because a dedicated HEPES monograph is not included in Ph. Eur. 11.2 or USP-NF 2024, the pharma-grade API is released against a vendor certificate of analysis that applies harmonised general chapters. Appearance is controlled as white or almost white crystalline powder; identification is confirmed by infrared absorption spectrophotometry and by a melting range or equivalent thermal method. Assay on the anhydrous basis is typically specified at 99.0–101.0%, with water content by Karl Fischer titration under USP <921> controlled at not more than 0.5% for injectable-grade material. Residue on ignition is limited to 0.1% by Ph. Eur. 2.4.14. Heavy metals are not specified by the obsolete USP <231> method alone; elemental impurities are controlled by USP <232>/<233> according to ICH Q3D Option 1 or Option 2. Residual solvents are limited under USP <467> for Class 2 and Class 3 solvents. Bacterial endotoxins are the critical injectable-grade discriminator: oral-grade vendor specifications commonly allow 2.5 EU/mg, whereas injectable-grade HEPES is released at 0.25 EU/mg or lower using Ph. Eur. 2.6.14 or USP <85>. A sulfated ash limit of 0.05% may be applied to high-purity lots. The user should request the actual lot CoA because non-compendial specifications are supplier-specific and must be justified in the drug submission.

Elemental impurity limits follow ICH Q3D Table A.2.2 for parenteral and oral routes; injectable products are evaluated for the parenteral permitted daily exposure, while oral products use the oral permitted daily exposure. Residual solvent control is normally set to USP <467> Class 2 limits for methanol, ethanol, acetone, and isopropanol if those solvents are used in HEPES synthesis; if the synthetic route uses acetonitrile or toluene, the corresponding Class 2 limits must be reported. The vendor should provide the synthetic route summary and a statement that no chlorinated solvents are used; otherwise, the user must test for Class 1 residual solvents such as carbon tetrachloride and 1,2-dichloroethane.

What processing constraints arise when HEPES is dry-mixed before tablet compression?

Unmilled HEPES crystals can produce poor flow in direct compression on a rotary tablet press equipped with a paddle feeder. If the vendor particle size specification is broad—for example, D₉₀ exceeding 200 µm—the powder may segregate from finer excipients and supply variable die-fill mass. Direct compression is therefore usually restricted to blends where HEPES is first co-milled or jet-milled to a controlled D₉₀ of 75–150 µm. Even after milling, HEPES is frequently placed in a dry granulation step using a roller compactor at roll force 10–20 kN/cm and screen mesh 0.8–1.2 mm to increase bulk density and flow. Wet granulation avoids many of these constraints because HEPES is dissolved in the binder solution and distributed at molecular level; however, the granulator impeller speed and binder addition rate must be adjusted to avoid sticking when the solution concentration exceeds 20% w/w. Published data for this specific configuration is limited; therefore, feasibility studies on the actual press and tooling are required before defining a control strategy. Capsule filling on a dosator-type capsule machine is more tolerant of low bulk density than tableting, but weight variation still increases if the powder is not densified or granulated.

In tablet development, the direct compression blend is evaluated per USP <1174> for powder flow. If the Hausner ratio exceeds 1.34, direct compression is usually not viable; if it is between 1.25 and 1.34, paddle feeder speed and fill cam can compensate but at the cost of higher weight variation. Compression force on a rotary press is often set between 8 and 20 kN for a 10–12 mm round tablet, but HEPES content and particle size alter compaction behavior; no universal force is applicable. Scale-up batches have shown that low-shear tumble blending for 15–30 min may not overcome size-exclusion segregation if the particle size difference between HEPES and excipients exceeds 100 µm. This is a process constraint distinct from chemical instability.

For wet granulation, HEPES is typically dissolved in purified water at 5–20% w/w and spray-added to the dry blend in a high-shear granulator. Impeller speed 200–400 rpm and chopper speed 1000–3000 rpm are used to produce granules; endpoint is judged by power consumption or torque, not by fixed time, because the buffer solution changes liquid binder viscosity. The granulate is dried in a fluid-bed dryer at inlet air temperature 50–70 °C and product temperature 30–40 °C to reach loss-on-drying 1.0–2.0% before lubrication. In tablet formulations, HEPES is used as a pH modifier at 0.5–2.0% w/w; higher levels can increase disintegration time because the soluble component leaves a porous matrix that may gel locally if uncontrolled moisture is present. For hard gelatin capsules, a milled or granulated HEPES blend with Hausner ratio below 1.25 is acceptable for automatic encapsulation. For injectable solutions, HEPES is dissolved in Water for Injection at 10–50 mM, pH-adjusted with 1 M sodium hydroxide or hydrochloric acid to 7.4, and sterile-filtered through a 0.22 µm PVDF or polyethersulfone membrane. In lyophilized formulations, HEPES is used at 10–25 mM because it provides pH stabilization without the calcium phosphate precipitation observed with phosphate buffers during freeze-concentration; the collapse temperature of the formulation, not HEPES alone, determines the lyophilization cycle.

For injectable solutions, the pH adjustment step must account for the temperature dependence of the pK_a. A solution adjusted to pH 7.4 at room temperature may drop below pH 7.2 at cold storage; this shift is smaller than that of Tris but still must be verified by a stability-indicating pH method. The final solution is sterile-filtered through a 0.22 µm membrane and filled into glass vials or prefilled syringes under nitrogen if oxygen-sensitive. Terminal moist-heat sterilization at 121 °C for 15 min is commonly used only after confirming no powder discoloration and no shift in assay; because HEPES is not volatile, loss on drying after autoclaving is not relevant but degradation products require control.

Low metal complexation, ultraviolet transparency, and temperature-dependent pH behavior

The zwitterionic structure of HEPES contains a piperazine nitrogen and a sulfonic acid group; the buffer equilibrium is localized on the piperazine ring. Its pK_a shifts with temperature at approximately -0.014 units/°C, so a solution prepared at 20 °C to pH 7.5 will exhibit pH near 7.26 at 37 °C. Buffer capacity is therefore calculated for the use temperature, not the preparation temperature. HEPES shows low binding to Ca²⁺ and Mg²⁺, making it suitable for injectable formulations where phosphate would form insoluble precipitates. Published data indicate weak interaction with Cu²⁺; therefore, HEPES is not the preferred buffer in copper-dependent enzymatic or analytical systems. Ultraviolet transparency is satisfactory for spectrometric detection: at 10–50 mM there is no significant absorbance above 240 nm, but the user should verify the solvent blank against the specific detection wavelength. Because HEPES is non-volatile and zwitterionic, it remains in the product and contributes to tonicity; osmolality of a 50 mM solution must be accounted for in parenteral formulation. The free-acid material is acidic when dissolved; pH adjustment with sodium hydroxide forms the sodium salt in situ and contributes sodium ion load.

The buffer also has low absorbance in the visible range; suppliers typically report absorbance at 260 nm and 280 nm for a 1 M aqueous solution to demonstrate compliance with bioprocess uses. HEPES is not added to formulations for its own therapeutic activity; it is a pH-control agent. Its contribution to osmolality should be calculated from the final molarity using ideal osmolarity plus measured osmotic coefficient when available. In freeze-dried formulations, HEPES may remain amorphous if the formulation contains a suitable lyoprotectant; if HEPES crystallizes during heat treatment, pH control in the reconstituted solution may be retained but the product appearance may change.

When ultraviolet detection is used for an API, the HEPES blank spectrum should be collected at 210–400 nm. The limit of detection for an impurity in the presence of HEPES depends on the buffer concentration and the wavelength; because HEPES is non-UV-absorbing above 240 nm, it does not mask API peaks in standard HPLC methods. This is not true for all Good’s buffers; some contain aromatic or carbonyl groups that absorb in the same range.

When HEPES replaces Tris in parenteral or cell-based processing

Switching from Tris to HEPES changes the buffering range and the chemical reactivity profile. Tris has a pK_a of 8.1 at 20 °C and a temperature coefficient of approximately -0.028 units/°C; at 37 °C its pK_a falls to about 7.6, which is close to HEPES at that temperature. However, Tris is a primary amine, whereas HEPES is a secondary piperazine derivative, so Tris reacts with aldehydes, reducing sugars, and some crosslinking agents. HEPES avoids that reaction class, which is relevant for formulations containing glucose, lactose, or oxidizable drug substances. In contrast to phosphate, HEPES does not contribute to calcium phosphate precipitation, but phosphate has a lower temperature coefficient and fewer organic-carbon analytical interferences. HEPES is preferred over bicarbonate-based systems when the formulation is handled outside a CO₂ atmosphere because it does not require a gas phase. The user should not interchange HEPES with Tris or phosphate without adjusting pH, buffer capacity, tonicity, and excipient compatibility; the three buffers produce different ionic strengths and sodium equivalents at the same molar concentration.

For cell-based processing, HEPES is used in media at concentrations of 10–25 mM to maintain pH in closed systems without CO₂ incubation. Compared with bicarbonate/CO₂, HEPES eliminates the need for gas-phase equilibrium but does not provide nutritional buffering; therefore, it is often combined with bicarbonate rather than used as a complete replacement. Compared with MOPS and MES, HEPES centers its pH range at 7.4, which matches mammalian cell culture and injectable physiological targets; MES is unsuitable for pH above 6.7. A switch from MOPS or MES to HEPES therefore requires re-qualification of the dissolution, buffering, and osmolality profile under the final storage condition.

In oral solid dosage forms, HEPES may be selected over Tris when the formulation contains lactose or other reducing sugars, because the Maillard reaction with Tris can generate colored products and reduce assay. Phosphate and glycine do not possess the same secondary-amine advantage, but glycine has a much lower pK_a and phosphate has precipitation issues. These differences are product-selection criteria when a pH modifier must be chosen for a specific tableting, encapsulation, granulation, or parenteral process.